Lean transformation in pharmaceuticals and healthcare manufacturing has to work inside validated processes, batch records, and change control, not around them. True North Solutions builds value stream mapping and automation analysis that starts from your real process data, so recommendations are grounded in what is actually validated and running, not a generic lean template lifted from discrete manufacturing.
Process Miner reads ERP event logs and Takt Time data to reconstruct the value stream that actually ran, including deviations from the validated process. That gives quality and operations teams a shared, data-backed picture of where cycle time is actually lost, whether that is changeover, hold times, or queueing between validated steps.
Microbot Miner scores candidate processes against a 7-criteria readiness rubric and produces a ranked backlog of automation opportunities with Power Automate flow designs. Deployment to the Power Platform only happens after a human has reviewed and approved it, which matters where any process change carries regulatory implications.
ESG Risk Analyzer drafts an environmental, social, and governance risk assessment across your Tier 1, 2, and 3 suppliers, including active pharmaceutical ingredient and excipient sourcing. Every output is scored against a fixed audit rubric before it reaches you, with a documented quality score and audit trail.
The five-day assessment runs these tools against your own data before any commitment to a full engagement. See Agentic AI Solutions and Lean Digital Transformation for the broader methodology.
Yes, but the constraints are different from general manufacturing. Value stream mapping has to account for validated processes, batch record requirements, and change control, rather than assuming every step can be freely rearranged. Process Miner works from your actual ERP event logs, so the map reflects the validated process as it actually runs.
Microbot Miner scores automation candidates against a 7-criteria readiness rubric and produces a ranked backlog. Any deployment to production only happens after a human reviews and approves it, which matters in a validated environment where changes carry regulatory weight.
ESG Risk Analyzer drafts a risk assessment across Tier 1, 2, and 3 suppliers, which in pharma often means active pharmaceutical ingredient sourcing and excipient supply. The output is scored against a fixed audit rubric and includes a documented quality score, useful as supporting evidence in supplier qualification reviews.